Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
20
10
2020
entrez:
21
11
2020
pubmed:
22
11
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
Recent research suggests that baseline body mass index (BMI) is associated with response to immunotherapy. In this study, we test the hypothesis that worsening nutritional status prior to the start of immunotherapy, rather than baseline BMI, negatively impacts immunotherapy response. We studied 629 patients with advanced cancer who received immune checkpoint blockade at New York University. Patients had melanoma (n=268), lung cancer (n=128) or other primary malignancies (n=233). We tested the association between BMI changes prior to the start of treatment, baseline prognostic nutritional index (PNI), baseline BMI category and multiple clinical end points including best overall response (BOR), objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Decreasing pretreatment BMI and low PNI were associated with worse BOR (p Standard of care measures of worsening nutritional status more accurately associate with immunotherapy outcomes than static measurements of BMI. Future studies should focus on determining whether optimizing pretreatment nutritional status, a modifiable variable, leads to improvement in immunotherapy response.
Sections du résumé
BACKGROUND
Recent research suggests that baseline body mass index (BMI) is associated with response to immunotherapy. In this study, we test the hypothesis that worsening nutritional status prior to the start of immunotherapy, rather than baseline BMI, negatively impacts immunotherapy response.
METHODS
We studied 629 patients with advanced cancer who received immune checkpoint blockade at New York University. Patients had melanoma (n=268), lung cancer (n=128) or other primary malignancies (n=233). We tested the association between BMI changes prior to the start of treatment, baseline prognostic nutritional index (PNI), baseline BMI category and multiple clinical end points including best overall response (BOR), objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).
RESULTS
Decreasing pretreatment BMI and low PNI were associated with worse BOR (p
CONCLUSION
Standard of care measures of worsening nutritional status more accurately associate with immunotherapy outcomes than static measurements of BMI. Future studies should focus on determining whether optimizing pretreatment nutritional status, a modifiable variable, leads to improvement in immunotherapy response.
Identifiants
pubmed: 33219093
pii: jitc-2020-001674
doi: 10.1136/jitc-2020-001674
pmc: PMC7682457
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA225450
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231295
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Trends Mol Med. 2017 May;23(5):451-464
pubmed: 28396056
PLoS One. 2014 Sep 29;9(9):e108687
pubmed: 25265392
J Immunother Cancer. 2019 Mar 29;7(1):89
pubmed: 30922394
Eur J Clin Nutr. 2020 Nov;74(11):1519-1535
pubmed: 32366995
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Lung Cancer (Auckl). 2017 Dec 08;8:249-257
pubmed: 29263709
Br J Cancer. 2012 Sep 4;107(6):988-93
pubmed: 22878374
J Natl Cancer Inst. 2012 Mar 7;104(5):371-85
pubmed: 22345712
Support Care Cancer. 2015 Jul;23(7):1933-9
pubmed: 25492636
J Cachexia Sarcopenia Muscle. 2015 Sep;6(3):197-207
pubmed: 26401465
Ann Palliat Med. 2019 Jan;8(1):24-32
pubmed: 30525765
Oncoimmunology. 2020 Apr 16;9(1):1751548
pubmed: 32363123
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
PLoS One. 2018 Oct 1;13(10):e0204729
pubmed: 30273398
Am J Clin Nutr. 2013 Oct;98(4):1012-9
pubmed: 23966429
Am J Clin Nutr. 2012 Dec;96(6):1346-53
pubmed: 23134880
Tumour Biol. 2015 May;36(5):3389-97
pubmed: 25527156
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Gastroenterol Rep (Oxf). 2016 Nov;4(4):272-280
pubmed: 27174435
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Tohoku J Exp Med. 2015;236(4):297-304
pubmed: 26250537
J Immunother Cancer. 2019 Aug 19;7(1):222
pubmed: 31426863
Int J Clin Oncol. 2019 Oct;24(10):1301-1310
pubmed: 31073814
Lung Cancer Manag. 2020 Apr 24;9(2):LMT31
pubmed: 32346405
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lung Cancer. 2019 Oct;136:45-51
pubmed: 31437663
Anticancer Res. 2019 Apr;39(4):2169-2176
pubmed: 30952764
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849
pubmed: 29891725
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
JAMA Oncol. 2020 Apr 1;6(4):512-518
pubmed: 31876896
Front Immunol. 2019 Aug 14;10:1940
pubmed: 31475003
J Clin Oncol. 2009 Jun 1;27(16):2692-6
pubmed: 19332724
Sci Rep. 2017 Jun 12;7(1):3285
pubmed: 28607442
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588
pubmed: 28653357
Sci Rep. 2020 Jan 29;10(1):1456
pubmed: 31996766